These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1197271)

  • 1. Parathyroid suppressibility in renal osteodystrophy.
    Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Ku G; Sweatman AJ; Wills MR
    Proc Eur Dial Transplant Assoc; 1975; 11():465-72. PubMed ID: 1197271
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma hydroxyproline in renal osteodystrophy.
    Varghese Z; Moorhead JF; Tatler GL; Baillod RA; Wills MR
    Proc Eur Dial Transplant Assoc; 1973; 10(0):187-96. PubMed ID: 4802560
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteodystrophy of dialysed patients treated with vitamin D.
    Verberckmoes R; Bouillon R; Krempien B
    Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
    [No Abstract]   [Full Text] [Related]  

  • 4. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 5. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 6. Parathyroid function in uremic children with and without osteodystrophy.
    Roof BS; Piel CF; Rames L; Potter D; Gordan GS
    Pediatrics; 1974 Mar; 53(3):404-9. PubMed ID: 4815261
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum hydroxyproline and renal osteodystrophy in patients maintained on haemodialysis.
    Goulding A; McChesney R; Irvine RO; Dixon SR
    N Z Med J; 1974 Dec; 80(530):540-4. PubMed ID: 4615274
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
    Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
    Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
    [No Abstract]   [Full Text] [Related]  

  • 10. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 11. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis].
    Fournier A; Bordier P; Weil B; Safar M; Idatte JM
    Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047
    [No Abstract]   [Full Text] [Related]  

  • 12. Parathyroid function in chronic vitamin D deficiency in man: a model for comparison with chronic renal failure.
    Stanbury SW; Lumb GA
    Calcif Tissue Res; 1976 Aug; 21 Suppl():185-201. PubMed ID: 953806
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of biochemical with radiological findings in renal osteodystrophy.
    Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Wills MR
    Ann Clin Biochem; 1975 May; 12(3):126-31. PubMed ID: 15637920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroidectomy in children with chronic renal failure.
    Firor HV; Moore ES; Levitsky LL; Galvez M
    J Pediatr Surg; 1972; 7(5):565-72. PubMed ID: 5083161
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of pyrophosphate in renal osteodystrophy.
    David DS; Sakai S; Granda J; Cheigh JS; Riggio RR; Stenzel KH; Rubin AL
    Trans Am Soc Artif Intern Organs; 1973; 19():440-5. PubMed ID: 4352991
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis.
    Buccianti G; Bianchi ML; Valenti G; Lorenz M; Cresseri D
    Nephron; 1990; 56(4):353-6. PubMed ID: 2079992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological, hormonal, biochemical and radiological evaluation of vit. D therapy in osteodystrophy patients on RDT.
    Brancaccio D; Graziani G; Faccini JM; Banfi G; Pedoja G; Watson L
    J Urol Nephrol (Paris); 1976; 82(4-5):359-62. PubMed ID: 940182
    [No Abstract]   [Full Text] [Related]  

  • 19. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ; Houston IB
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.